Womens Health Diagnostics Market to Record Ascending Growth by 2027| Abbott Laboratories, Becton, Dickinson and Company, Carestream Health, F. Hoffmann-La Roche AG, GE Healthcare, Hologic, Koninklijke Philips N.V., Quest Diagnostics, Siemens AG, Cardinal

The global women's health diagnostics market was valued at $13,133 million in 2016, and is projected to reach $21,501 million in 2023 at a CAGR of 7.0% from 2017 to 2023. Women are more prone to obesity and reproduction related issues as compared to men. Women's health diagnostics include screening, testing or diagnosing, and monitoring of several women-related disorders namely breast cancer, ovarian, cancer, cervical cancer, menopause, and pregnancy.

Check for the sample here - https://bit.ly/2AGViDk

Rise in number of chronic and lifestyle disorders, which lead to various cancer such as breast cancer is the major factor that contributes to the growth of the women's health diagnostics market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market.
Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.

The List of companies covered in this Reports are:
Abbott Laboratories
Becton, Dickinson and Company
Carestream Health
F. Hoffmann-La Roche AG
GE Healthcare
Hologic, Inc.
Koninklijke Philips N.V.
Quest Diagnostics Inc.
Siemens AG
Cardinal Health

The global women's health diagnostics market is segmented on the basis of type, end user, and region. By type, it is classified into diagnostic devices, diagnostic tests, and accessories and consumables. The diagnostic devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound imaging systems, mammography systems, MRI systems, and nuclear imaging. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system.

Diagnostic tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing. Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests.

Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening and carrier testing includes tests for cystic fibrosis and other diseases. The pregnancy and ovulation testing segment is further bifurcated into lab-based pregnancy and ovulation testing, and home-based pregnancy and ovulation testing. Depending on end user, it is categorized into hospitals and clinics, home care settings, diagnostic and imaging centers, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Inquire For Discount: https://bit.ly/2MxHWvP

Contact Info:
Name: Sameer Joshi
Email: sales@premiummarketinsights.com
Organization: Premium Market Insights
Phone: +1-646-491-9876

About Premium Market Insights:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider.

This release was published on openPR.